InvestorsHub Logo
Followers 145
Posts 27566
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Sunday, 03/27/2022 8:59:07 AM

Sunday, March 27, 2022 8:59:07 AM

Post# of 2028
Dawson James Keeps Their Buy Rating on Can-Fite BioPharma (CANF)

March 27 2022 - 08:15AM

Dawson James analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma (CANF – Research Report) on March 25 and set a price target of $9.00. The company's shares closed last Friday at $1.20. According to TipRanks.com, Kolbert is a 3-star analyst with an average return of 2.5% and a 39.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Currently, the analyst consensus on Can-Fite BioPharma is a Moderate Buy with an average price target of $7.00.
https://www.tipranks.com/news/blurbs/dawson-james-keeps-their-buy-rating-on-can-fite-biopharma-canf?utm_source=advfn.com&utm_medium=referral
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CANF News